323 related articles for article (PubMed ID: 19217565)
1. [Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].
Maroto Hernando M; Soler Palacín P; Martin Nalda N; Oliveras Arenas M; Español Boren T; Figueras Nadal C
An Pediatr (Barc); 2009 Feb; 70(2):111-9. PubMed ID: 19217565
[TBL] [Abstract][Full Text] [Related]
2. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.
Gardulf A; Nicolay U; Math D; Asensio O; Bernatowska E; Böck A; Costa-Carvalho BT; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Matamoros N; Niehues T; Schmidt S; Schulze I; Borte M
J Allergy Clin Immunol; 2004 Oct; 114(4):936-42. PubMed ID: 15480339
[TBL] [Abstract][Full Text] [Related]
3. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases.
Haddad É; Barnes D; Kafal A
Transfus Apher Sci; 2012 Jun; 46(3):315-21. PubMed ID: 22503304
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
Stein MR; Koterba A; Rodden L; Berger M
Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.
Eftimov F; Vermeulen M; de Haan RJ; van den Berg LH; van Schaik IN
J Peripher Nerv Syst; 2009 Jun; 14(2):93-100. PubMed ID: 19691531
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous immunoglobulin therapy in an 11-year-old patient with common variable immunodeficiency and von Willebrand disease.
Arora R; Newton TC; Nelson MR
Ann Allergy Asthma Immunol; 2007 Oct; 99(4):367-70. PubMed ID: 17941286
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
Berger M; Rojavin M; Kiessling P; Zenker O
Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
[TBL] [Abstract][Full Text] [Related]
9. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
10. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency.
Pourpak Z; Aghamohammadi A; Sedighipour L; Farhoudi A; Movahedi M; Gharagozlou M; Chavoshzadeh Z; Jadid L; Rezaei N; Moin M
J Microbiol Immunol Infect; 2006 Apr; 39(2):114-20. PubMed ID: 16604243
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy.
Gardulf A; Borte M; Ochs HD; Nicolay U;
Clin Immunol; 2008 Jan; 126(1):81-8. PubMed ID: 17964220
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
Shapiro RS
Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID).
Bayrakci B; Ersoy F; Sanal O; Kiliç S; Metin A; Tezcan I
Turk J Pediatr; 2005; 47(3):239-46. PubMed ID: 16250308
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
[No Abstract] [Full Text] [Related]
16. Intravenous immunoglobulin (IVIG) efficiency in women with common variable immunodeficiency (CVID) decreases significantly during pregnancy.
Egawa M; Kanegane H; Imai K; Morio T; Miyasaka N
J Matern Fetal Neonatal Med; 2019 Sep; 32(18):3092-3096. PubMed ID: 29614902
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin treatment in primary antibody deficiency.
Maarschalk-Ellerbroek LJ; Hoepelman IM; Ellerbroek PM
Int J Antimicrob Agents; 2011 May; 37(5):396-404. PubMed ID: 21276714
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency.
Fasth A; Nyström J
Acta Paediatr; 2007 Oct; 96(10):1474-8. PubMed ID: 17850391
[TBL] [Abstract][Full Text] [Related]
19. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
20. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
